×
About 2,050 results

ALLMedicine™ Adrenocortical Carcinoma Center

Research & Reviews  745 results

Clinical significance of cyclin-dependent kinase inhibitor 2C expression in cancers: fr...
https://doi.org/10.1186/s12890-022-02036-5 10.2991/jegh.k.191008.001 10.1515/med-2021-0321 10.1016/j.cllc.2021.07.011 10.3322/caac.21654 10.3390/cancers12092522 10.1016/j.biopha.2020.111111 10.1002/2211-5463.12819 10.3389/fonc.2020.01546 10.1016/j.surg.2019.03.041 10.1007/s40618-017-0783-y 10.1371/journal.pgen.0030161 10.1002/cam4.4285 10.7717/peerj.11968 10.1186/s12916-021-02027-z 10.1186/1471-2105-12-77 10.1186/s12935-021-02278-z 10.1186/s12916-021-02134-x 10.1093/nar/gky1094 10.1093/nar/gkw983 10.1186/s12967-021-02915-1 10.1002/2211-5463.13256 10.1186/s12920-021-01007-9 10.1093/nar/gkab1113 10.1093/bioinformatics/btr064 10.1089/omi.2011.0118 10.7717/peerj.12253 10.2147/IJGM.S333697 10.1038/nature08822 10.1186/s12885-021-08796-3 10.1016/j.ebiom.2020.103074 10.1016/j.immuni.2018.03.023 10.1158/0008-5472.CAN-17-0307 10.1038/ncomms3612 10.1093/bioinformatics/btz210 10.1136/ebmental-2019-300117 10.1038/nature14664 10.3389/fimmu.2020.00369 10.1093/jnci/djy085 10.5858/2002-126-0042-IAOPAP 10.1002/hep.20337 10.1128/MCB.23.4.1269-1277.2003 10.1530/ERC-13-0445 10.1093/annonc/mdy495 10.3390/cells9040801 10.1016/j.celrep.2018.03.124 10.1007/s11684-016-0478-3 10.1038/srep13781
BMC Pulmonary Medicine; Li GS, Chen G et. al.

Jun 25th, 2022 - Cyclin-dependent kinase inhibitor 2C (CDKN2C) was identified to participate in the occurrence and development of multiple cancers; however, its roles in small cell lung carcinoma (SCLC) remain unclear. Differential expression analysis of CDKN2C be...

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04447014

Jun 24th, 2022 - Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75-90% and an average survival from the time of diagnosis o...

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
https://clinicaltrials.gov/ct2/show/NCT05237934

Jun 24th, 2022 - Background: Neuroendocrine neoplasms (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring for example in the gastrointestinal tract, islets of the pancreas, lung, adrenal ...

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04358107

Jun 24th, 2022 - Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mon...

see more →

Guidelines  3 results

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practi...
https://doi.org/10.1530/EJE-16-0467
European Journal of Endocrinology; Fassnacht M, Arlt W et. al.

Jul 9th, 2016 - : By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent con...

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an end...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

see more →

Clinicaltrials.gov  45 results

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04447014

Jun 24th, 2022 - Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75-90% and an average survival from the time of diagnosis o...

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
https://clinicaltrials.gov/ct2/show/NCT05237934

Jun 24th, 2022 - Background: Neuroendocrine neoplasms (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring for example in the gastrointestinal tract, islets of the pancreas, lung, adrenal ...

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04358107

Jun 24th, 2022 - Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mon...

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
https://clinicaltrials.gov/ct2/show/NCT03583710

Jun 8th, 2022 - PRIMARY OBJECTIVE: I. To compare the effect of adjuvant mitotane treatment alone (arm A) with that of adjuvant mitotane combined with four 21-day cycles of etoposide/cisplatin (arm B) on recurrence-free survival (RFS) in patients with high-risk ad...

Evaluation of Side Effects of Mitotane
https://clinicaltrials.gov/ct2/show/NCT00568139

May 19th, 2022 - Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many side effects are not well documented. Therefore, we are aiming at collecting data about side effects in patients treated with mitotane

see more →

News  25 results

Exceptional Responder Provides Treatment Clues in Bladder Cancer
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer

Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...

Neuroendocrine Tumors Clinical Practice Guidelines (NCCN, 2021)
https://www.medscape.com/viewarticle/959868

Sep 30th, 2021 - Updated clinical guidelines on the diagnosis and management of neuroendocrine and adrenal tumors were released in 2021 by the National Comprehensive Cancer Network (NCCN). The new version of the guidelines, published in the Journal of the National...

Advanced HCC: What's Next?
https://www.onclive.com/view/advanced-hcc-whats-next

Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: I would like to end our very valuable discussion here by asking each one of you about—all right, great, out of nothing we moved in the speed of light. I’m not sure even if there is any other disease that w...

Urine Screen as Part of Triple Test Improves ID of Adrenal Cancer
https://www.medscape.com/viewarticle/934790

Jul 29th, 2020 - A strategy that includes a urine steroid test along with imaging characteristics and tumor size criteria can significantly improve the challenging diagnosis of adrenocortical cancer, helping to avoid unnecessary, and often unsuccessful, further im...

Adrenocortical Carcinoma Clinical Practice Guidelines (2018)
https://reference.staging.medscape.com/viewarticle/904250

Nov 5th, 2018 - Clinical practice guidelines for the management of adrenocortical carcinoma in adults were released in October 2018 by the European Society of Endocrinology.[1] Diagnosis Perform a detailed hormonal workup of all patients with suspected adrenocort...

see more →

Patient Education  2 results see all →